Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Recombinant murine interleukin-12 elicits potent antileukemic immune responses in a murine model of philadelphia chromosome-positive acute lymphoblastic leukemia

Cancer Gene Therapy volume 12, pages 818–824 (2005)Cite this article

Abstract

Despite the success of chemotherapy regimens in the treatment of acute lymphoblastic leukemia (ALL), certain subsets of patients have a high rate of induction failure and subsequent relapse. One of these subsets of patients carry a translocation between chromosomes 9 and 22, the so called Philadelphia chromosome (Ph+). The result of this translocation is the fusion oncogene, Bcr-Abl, which is uniquely expressed in the leukemia clone, and as such has the potential to initiate antileukemic immune responses against the leukemia blasts. We utilized a murine model of Ph+ ALL to look at the ability of systemic interleukin 12 (IL-12) treatments to initiate antileukemic immune responses, and studied the mechanisms by which it does so. We found that IL-12 was able to eliminate pre-established leukemia, and that this protection was mediated by CD4, CD8, and NK cells in combination. While IL-12 was able to eliminate pre-established leukemia, it did not elicit immunologic memory. Consistent with previous work, vaccination with irradiated leukemia cells transduced with immunomodulator genes was able to establish long-term memory, and, when used with IL-12, was able to eradicate pre-existing disease and induce resistance to subsequent leukemia challenge. These studies demonstrate the feasibility of an immunotherapeutic approach towards the treatment of Ph+ ALL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Niemeyer CM, Sallan SE . Acute lymphoblastic leukemia. In: Nathan DG, Oski FA, eds. Hematology of Infancy and Childhood. Philadelphia, PA: Saunders; 1998: 1249.

    Google Scholar 

  2. Uckun FM, Nachman JB, Sather HN, et al. Clinical significance of philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer. 1998;83:2030–2039.

    Article  CAS  PubMed  Google Scholar 

  3. Pui CH, Relling MV, Downing JR . Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535–1548.

    Article  CAS  PubMed  Google Scholar 

  4. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–1042.

    Article  CAS  PubMed  Google Scholar 

  5. Kwak LW . Approaches for immunotherapy of lymphomas. Immunol Invest. 2000;29:93–95.

    Article  CAS  PubMed  Google Scholar 

  6. Dranoff G . GM-CSF secreting melanoma vaccines. Oncogene. 2003;22:3188–3192.

    Article  CAS  PubMed  Google Scholar 

  7. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003;63:2127–2133.

    CAS  PubMed  Google Scholar 

  8. Stripecke R, Skelton DC, Gruber T, et al. Immune response to Philadelphia chromosome positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage-colony-stimulating factor. Hum Gene Ther. 1998;9:2049–2062.

    Article  CAS  PubMed  Google Scholar 

  9. Stripecke R, Skelton DC, Pattengale PK, Shimada H, Kohn DB . Combination of CD80 and granulocyte macrophage colony stimulating factor co-expression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome positive acute lymphoblastic leukemia. Hum Gene Ther. 1999;10:2109–2122.

    Article  CAS  PubMed  Google Scholar 

  10. Gruber TA, Skelton DC, Kohn DB . Requirement for Natural Killer cells in CD40 ligand mediated rejection of Philadelphia chromosome positive acute lymphoblastic leukemia cells. J Immunol. 2002;168:73–80.

    Article  CAS  PubMed  Google Scholar 

  11. Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature. 2003;3:133–146.

    CAS  Google Scholar 

  12. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Expr Med. 1993;178:1223–1230.

    Article  CAS  Google Scholar 

  13. Cavallo F, Signorelli P, Giovarelli M, et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst. 1997;89:1049–1058.

    Article  CAS  PubMed  Google Scholar 

  14. Smyth MJ, Taniguchi M, Street SEA . The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol. 2000;165:2665–2670.

    Article  CAS  PubMed  Google Scholar 

  15. Dunussi-Joannopoulos K, Runyon K, Erickson J, Schau RG, Hawley RG, Leonard JP . Vaccines with interleukin 12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood. 1999;94:4263–4273.

    CAS  PubMed  Google Scholar 

  16. Cui J, Shin T, Kawano T, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278:1623–1626.

    Article  CAS  PubMed  Google Scholar 

  17. Smiley ST, Kaplan MH, Grusby MJ . Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science. 1997;275:977–979.

    Article  CAS  PubMed  Google Scholar 

  18. Mascarenhas L, Stripecke R, Case SS, Xu D, Weinberg KI, Kohn DB . Gene Delivery to Human B-precursor acute lymphoblastic leukemia cells. Blood. 1998;92:3537–3545.

    CAS  PubMed  Google Scholar 

  19. Stripecke R, Cardoso AA, Pepper KA, et al. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage-colony-stimulating factor in human acute lymphoblastic Leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood. 2000;96:1317–1326.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Lora Barsky for assistance in flow cytometry and Fred Dorey, PhD for statistical analysis. This work was supported in part by the Kenneth T and Eileen J Norris Foundation.

Author information

Authors and Affiliations

  1. Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, USA

    Tanja A Gruber, Dianne C Skelton & Donald B Kohn

  2. Department of Pediatrics, Keck School of Medicine, University of Southern California, USA

    Donald B Kohn

  3. Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, USA

    Donald B Kohn

Authors
  1. Tanja A Gruber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dianne C Skelton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donald B Kohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald B Kohn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gruber, T., Skelton, D. & Kohn, D. Recombinant murine interleukin-12 elicits potent antileukemic immune responses in a murine model of philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Gene Ther 12, 818–824 (2005). https://doi.org/10.1038/sj.cgt.7700839

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700839

Keywords

This article is cited by

Search

Advanced search

Quick links